The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Most drugs get the nod in the US before Europe – but there are some cases where the usual trend is reversed.
After the recent EU positive opinion for Aveo's tivozanib, EP Vantage takes a look at other projects approved in the EU, but not the US.